GSK’s Focuses Bioelectronics Quest On Blocking Single-Organ Neural Signals
This article was originally published in The Pink Sheet Daily
Executive Summary
In the final part of its three-prong effort to advance the nascent field of bioelectronics, GSK will award a $1 million prize to researchers who are first able to solve the single-organ nerve interface challenge. Previously, the pharma launched its bioelectronics R&D unit and Action Potential Venture Capital to spur progress in this area.
You may also be interested in...
GSK Ventures Into The Device World Through Bioelectronic Investment
The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.
Recent And Upcoming FDA Advisory Committee Meetings
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
OIG: FDA’s EUA Approach Allowed Bad Tests To Reach Market
A review by a government watchdog found the FDA’s review process for COVID-19 diagnostics was plagued by issues including allowing low-quality tests to slip through, high reviewer workloads, and manufacturer frustration.